These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9342554)

  • 1. Ocular-specific chemical delivery systems of betaxolol for safe local treatment of glaucoma.
    Farag HH; Wu WM; Barros MD; Somogyi G; Prokai L; Bodor N
    Drug Des Discov; 1997 Aug; 15(2):117-30. PubMed ID: 9342554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 5-HT(1A)Receptor agonist 8-OH-DPAT lowers intraocular pressure in normotensive NZW rabbits.
    Chidlow G; Nash MS; De Santis LM; Osborne NN
    Exp Eye Res; 1999 Dec; 69(6):587-93. PubMed ID: 10620387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Nanocapsules of beta-blocking agents: a new drug carrier in ophthalmology. Application to medical treatment of glaucoma in rabbits].
    Marchal-Heussler L; Sirbat D; Hoffman M; Maincent P
    J Fr Ophtalmol; 1991; 14(6-7):371-5. PubMed ID: 1685738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular-specific delivery of timolol by sequential bioactivation of its oxime and methoxime analogs.
    Bodor N; Farag HH; Somogyi G; Wu WM; Barros MD; Prokai L
    J Ocul Pharmacol Ther; 1997 Oct; 13(5):389-403. PubMed ID: 9326721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-653,328: an ocular hypotensive agent with modest beta receptor blocking activity.
    Sugrue MF; Gautheron P; Grove J; Mallorga P; Viader MP; Baldwin JJ; Ponticello GS; Varga SL
    Invest Ophthalmol Vis Sci; 1988 May; 29(5):776-84. PubMed ID: 2896641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of long-term topical betaxolol on tissue circulation in the iris and optic nerve head.
    Araie M; Muta K
    Exp Eye Res; 1997 Feb; 64(2):167-72. PubMed ID: 9176049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical flunarizine reduces IOP and protects the retina against ischemia-excitotoxicity.
    Osborne NN; Wood JP; Cupido A; Melena J; Chidlow G
    Invest Ophthalmol Vis Sci; 2002 May; 43(5):1456-64. PubMed ID: 11980861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An in vitro approach to investigate ocular metabolism of a topical, selective β1-adrenergic blocking agent, betaxolol.
    Bushee JL; Dunne CE; Argikar UA
    Xenobiotica; 2015 May; 45(5):396-405. PubMed ID: 25475994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentrations of betaxolol in ocular tissues of patients with glaucoma and normal monkeys after 1 month of topical ocular administration.
    Holló G; Whitson JT; Faulkner R; McCue B; Curtis M; Wieland H; Chastain J; Sanders M; DeSantis L; Przydryga J; Dahlin DC
    Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):235-40. PubMed ID: 16384968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of treatment by medicine or surgery on intraocular pressure and pulsatile ocular blood flow in normal-pressure glaucoma.
    Poinoosawmy D; Indar A; Bunce C; Garway-Heath DF; Hitchings RA
    Graefes Arch Clin Exp Ophthalmol; 2002 Sep; 240(9):721-6. PubMed ID: 12271368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats.
    Fukano Y; Kawazu K
    Drug Metab Dispos; 2009 Aug; 37(8):1622-34. PubMed ID: 19477946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischaemia to the retina.
    Osborne NN; DeSantis L; Bae JH; Ugarte M; Wood JP; Nash MS; Chidlow G
    Exp Eye Res; 1999 Sep; 69(3):331-42. PubMed ID: 10471341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol.
    Inan UU; Ermis SS; Orman A; Onrat E; Yucel A; Ozturk F; Asagidag A; Celik A
    J Ocul Pharmacol Ther; 2004 Aug; 20(4):293-310. PubMed ID: 15321024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension.
    Buckley MM; Goa KL; Clissold SP
    Drugs; 1990 Jul; 40(1):75-90. PubMed ID: 2202584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of the effectiveness of beta-blockers for intraocular pressure and visual field in primary open-angle glaucoma].
    Dobre X
    Oftalmologia; 2008; 52(4):95-9. PubMed ID: 19354170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Betaxolol hydrochloride loaded chitosan nanoparticles for ocular delivery and their anti-glaucoma efficacy.
    Jain K; Kumar RS; Sood S; Dhyanandhan G
    Curr Drug Deliv; 2013 Oct; 10(5):493-9. PubMed ID: 23410069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADRB1 and ADBR2 gene polymorphisms and the ocular hypotensive response to topical betaxolol in healthy Mexican subjects.
    Messina Baas O; Pacheco Cuellar G; Toral-López J; Lara Huerta SF; Gonzalez-Huerta LM; Urueta-Cuellar H; Rivera-Vega MR; Babayan-Mena I; Cuevas-Covarrubias SA
    Curr Eye Res; 2014 Nov; 39(11):1076-80. PubMed ID: 24749907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epinephrine distribution after topical administration to phakic and aphakic eyes.
    Kramer SG
    Trans Am Ophthalmol Soc; 1980; 78():947-82. PubMed ID: 7257075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of betaxolol hydrochloride ophthalmic solution on intraocular pressures during transient microgravity.
    Pattinson TJ; Gibson CR; Manuel FK; Bishop SL; March WF
    Aviat Space Environ Med; 1999 Oct; 70(10):1012-7. PubMed ID: 10519481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Betaxolol and levobunolol: new beta-blocking antiglaucoma agents.
    Tierney DW
    J Am Optom Assoc; 1987 Sep; 58(9):722-7. PubMed ID: 2895783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.